NCT06247670 - Study of CMP-CPS-001 in Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 5, 2024

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2025

Conditions

Healthy Volunteers

Interventions

DRUG

CMP-CPS-001

CMP-CPS-001 consists of an antisense oligonucleotide solution that will be administered subcutaneously.

OTHER

Placebo

Placebo is 0.9% normal saline solution and will be administered subcutaneously.

Trial Locations (1)

RECRUITING

Nucleus Network Brisbane (also known as Q-Pharm Pty Ltd), Herston